Cargando…
Lipoic acid in secondary progressive MS: A randomized controlled pilot trial
OBJECTIVE: To determine whether lipoic acid (LA), an endogenously produced antioxidant, slowed the whole-brain atrophy rate and was safe in secondary progressive MS (SPMS). METHODS: Patients with SPMS aged 40–70 years enrolled in a single center, 2-year, double-blind, randomized trial of daily oral...
Autores principales: | Spain, Rebecca, Powers, Katherine, Murchison, Charles, Heriza, Elizabeth, Winges, Kimberly, Yadav, Vijayshree, Cameron, Michelle, Kim, Ed, Horak, Fay, Simon, Jack, Bourdette, Dennis |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5489387/ https://www.ncbi.nlm.nih.gov/pubmed/28680916 http://dx.doi.org/10.1212/NXI.0000000000000374 |
Ejemplares similares
-
Lipoic Acid Pharmacokinetics at Baseline and 1 year in Secondary Progressive MS
por: Bittner, Frank, et al.
Publicado: (2017) -
Lipoic Acid Attenuates Inflammation via cAMP and Protein Kinase A Signaling
por: Salinthone, Sonemany, et al.
Publicado: (2010) -
Oral lipoic acid as a treatment for acute optic neuritis: a blinded, placebo controlled randomized trial
por: Falardeau, Julie, et al.
Publicado: (2019) -
Falls in People with Multiple Sclerosis Compared with Falls in Healthy Controls
por: Mazumder, Rajarshi, et al.
Publicado: (2014) -
Recent developments in multiple sclerosis therapeutics
por: Spain, Rebecca I, et al.
Publicado: (2009)